Norland's heel bone density test cleared:
This article was originally published in Clinica
Executive Summary
The FDA has cleared Norland Medical Systems' new peripheral bone density measuring device which takes density readings at the heal. The portable Apollo DXA device will cost less than $20,000 and will be marketed at physicians' offices in the US. The company has struck a deal with Tokai Financial Services under which Tokai will provide financing for purchasers of the device.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.